Scilex Holding Company (SCLX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
25/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinSCLX / S&P 88.09% / 15.20% |
LoseSCLX / S&P -28.55% / 15.00% |
WinSCLX / S&P 797.11% / 50.40% |
| 2026-Q11/3 |
LoseSCLX / S&P -45.41% / -4.33% |
LoseSCLX / S&P -33.22% / 11.30% |
WinSCLX / S&P 598.96% / 27.70% |
| 2025-Q41/3 |
LoseSCLX / S&P -38.01% / 2.65% |
LoseSCLX / S&P -46.54% / 9.00% |
WinSCLX / S&P 207.34% / 13.40% |
| 2025-Q32/3 |
WinSCLX / S&P 234.13% / 8.12% |
LoseSCLX / S&P -26.82% / 4.61% |
WinSCLX / S&P 61.20% / 13.45% |
| 2025-Q20/3 |
LoseSCLX / S&P -32.42% / 10.94% |
LoseSCLX / S&P -12.98% / 4.83% |
LoseSCLX / S&P -67.18% / 10.63% |
| 2025-Q11/3 |
LoseSCLX / S&P -41.55% / -4.27% |
WinSCLX / S&P 7.79% / 4.98% |
LoseSCLX / S&P -38.40% / 10.57% |
| 2024-Q42/3 |
LoseSCLX / S&P -53.95% / 2.41% |
WinSCLX / S&P 21.07% / 5.25% |
WinSCLX / S&P 819.38% / 6.15% |
| 2024-Q32/3 |
LoseSCLX / S&P -52.07% / 5.89% |
WinSCLX / S&P 22.02% / 5.89% |
WinSCLX / S&P 1338.46% / 6.11% |
| 2024-Q23/3 |
WinSCLX / S&P 21.38% / 4.28% |
WinSCLX / S&P 9.41% / 5.38% |
WinSCLX / S&P 4342.11% / 5.12% |
| 2024-Q12/3 |
LoseSCLX / S&P -22.06% / 10.56% |
WinSCLX / S&P 12.54% / 5.71% |
WinSCLX / S&P 2837.50% / 5.59% |
| 2023-Q43/3 |
WinSCLX / S&P 45.71% / 11.69% |
WinSCLX / S&P 22.90% / 6.81% |
WinSCLX / S&P 658.82% / 7.78% |
| 2023-Q31/3 |
LoseSCLX / S&P -74.87% / -3.27% |
LoseSCLX / S&P SCLX unavailable / 7.52% |
WinSCLX / S&P 69.57% / -5.03% |
| 2023-Q20/3 |
LoseSCLX / S&P -32.07% / 8.74% |
LoseSCLX / S&P SCLX unavailable / 9.50% |
LoseSCLX / S&P -59.14% / -8.57% |
| 2023-Q11/3 |
WinSCLX / S&P 105.51% / 7.50% |
LoseSCLX / S&P SCLX unavailable / 10.77% |
LoseSCLX / S&P -60.49% / -15.69% |
| 2022-Q40/3 |
LoseSCLX / S&P -61.37% / 7.56% |
LoseSCLX / S&P SCLX unavailable / 11.88% |
LoseSCLX / S&P -73.85% / -17.99% |
| 2022-Q31/3 |
WinSCLX / S&P 1.08% / -4.88% |
LoseSCLX / S&P SCLX unavailable / 13.47% |
LoseSCLX / S&P SCLX unavailable / -1.41% |
| 2022-Q21/3 |
WinSCLX / S&P 0.39% / -16.10% |
LoseSCLX / S&P SCLX unavailable / 13.71% |
LoseSCLX / S&P SCLX unavailable / 11.04% |
| 2022-Q11/3 |
WinSCLX / S&P 1.39% / -4.60% |
LoseSCLX / S&P SCLX unavailable / 15.97% |
LoseSCLX / S&P SCLX unavailable / 42.23% |
| 2021-Q40/3 |
LoseSCLX / S&P 0.40% / 11.03% |
LoseSCLX / S&P SCLX unavailable / 15.00% |
LoseSCLX / S&P SCLX unavailable / 96.40% |
| 2021-Q31/3 |
WinSCLX / S&P 0.81% / 0.58% |
LoseSCLX / S&P SCLX unavailable / 10.77% |
LoseSCLX / S&P SCLX unavailable / 69.42% |
| 2021-Q20/3 |
LoseSCLX / S&P 0.40% / 8.55% |
LoseSCLX / S&P SCLX unavailable / 6.58% |
LoseSCLX / S&P SCLX unavailable / 51.81% |
| 2021-Q10/3 |
LoseSCLX / S&P SCLX unavailable / 6.17% |
LoseSCLX / S&P SCLX unavailable / -1.06% |
LoseSCLX / S&P SCLX unavailable / 7.39% |
| 2020-Q40/3 |
LoseSCLX / S&P SCLX unavailable / 12.15% |
LoseSCLX / S&P SCLX unavailable / -3.72% |
LoseSCLX / S&P SCLX unavailable / -33.42% |
| 2020-Q30/3 |
LoseSCLX / S&P SCLX unavailable / 8.93% |
LoseSCLX / S&P SCLX unavailable / -2.04% |
LoseSCLX / S&P SCLX unavailable / -27.10% |
| 2020-Q20/3 |
LoseSCLX / S&P SCLX unavailable / 20.54% |
LoseSCLX / S&P SCLX unavailable / -0.46% |
LoseSCLX / S&P SCLX unavailable / -27.11% |
| 2020-Q10/3 |
LoseSCLX / S&P SCLX unavailable / -19.60% |
LoseSCLX / S&P SCLX unavailable / 3.47% |
LoseSCLX / S&P SCLX unavailable / -14.75% |
| 2019-Q40/3 |
LoseSCLX / S&P SCLX unavailable / 9.07% |
LoseSCLX / S&P SCLX unavailable / 5.36% |
LoseSCLX / S&P SCLX unavailable / 2.99% |
| 2019-Q30/3 |
LoseSCLX / S&P SCLX unavailable / 1.70% |
LoseSCLX / S&P SCLX unavailable / 5.02% |
LoseSCLX / S&P SCLX unavailable / 0.21% |
| 2019-Q20/3 |
LoseSCLX / S&P SCLX unavailable / 4.30% |
LoseSCLX / S&P SCLX unavailable / 6.64% |
LoseSCLX / S&P SCLX unavailable / 8.65% |
| 2019-Q10/3 |
LoseSCLX / S&P SCLX unavailable / 13.65% |
LoseSCLX / S&P SCLX unavailable / 8.12% |
LoseSCLX / S&P SCLX unavailable / 14.29% |
| 2018-Q40/3 |
LoseSCLX / S&P SCLX unavailable / -13.52% |
LoseSCLX / S&P SCLX unavailable / 9.05% |
LoseSCLX / S&P SCLX unavailable / 18.23% |
| 2018-Q30/3 |
LoseSCLX / S&P SCLX unavailable / 7.71% |
LoseSCLX / S&P SCLX unavailable / 10.21% |
LoseSCLX / S&P SCLX unavailable / 19.06% |
| 2018-Q20/3 |
LoseSCLX / S&P SCLX unavailable / 3.43% |
LoseSCLX / S&P SCLX unavailable / 9.03% |
LoseSCLX / S&P SCLX unavailable / 14.46% |
| 2018-Q10/3 |
LoseSCLX / S&P SCLX unavailable / -0.76% |
LoseSCLX / S&P SCLX unavailable / 7.68% |
LoseSCLX / S&P SCLX unavailable / 12.46% |
| 2017-Q40/3 |
LoseSCLX / S&P SCLX unavailable / 6.64% |
LoseSCLX / S&P SCLX unavailable / 7.03% |
LoseSCLX / S&P SCLX unavailable / 13.82% |
| 2017-Q30/3 |
LoseSCLX / S&P SCLX unavailable / 4.48% |
LoseSCLX / S&P SCLX unavailable / 5.68% |
LoseSCLX / S&P SCLX unavailable / 17.57% |
| 2017-Q20/3 |
LoseSCLX / S&P SCLX unavailable / 3.09% |
LoseSCLX / S&P SCLX unavailable / 4.83% |
LoseSCLX / S&P SCLX unavailable / 17.74% |
| 2017-Q10/3 |
LoseSCLX / S&P SCLX unavailable / 6.07% |
LoseSCLX / S&P SCLX unavailable / 3.67% |
LoseSCLX / S&P SCLX unavailable / 13.32% |
| 2016-Q40/3 |
LoseSCLX / S&P SCLX unavailable / 3.82% |
LoseSCLX / S&P SCLX unavailable / 2.09% |
LoseSCLX / S&P SCLX unavailable / 7.05% |
| 2016-Q30/3 |
LoseSCLX / S&P SCLX unavailable / 3.85% |
LoseSCLX / S&P SCLX unavailable / 0.20% |
LoseSCLX / S&P SCLX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | SCLX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -49.63% | 20.78% |
| Annualized return | -49.63% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | SCLX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.44% | 83.14% |
| Annualized return | -51.96% | 12.86% |
10Y · 2021-03-05 to 2026-08-27
| Metric | SCLX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.41% | 319.30% |
| Annualized return | -30.59% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |